A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT06368167
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SHR2554 — DRUG
    SHR2554

Study Details

The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma

Key Dates

First listed
Apr 16, 2024
Start date
Apr 30, 2024
Status verified
Apr 2024
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
105 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR2554

Primary Outcome Measure

Objective response rate (ORR) assessed by independent review committee (IRC) [ Time Frame: around 1 year ]

Central Contacts

Related Studies